Bicara Therapeutics Inc. Common Stock

BCAX • Biotechnology

$23.17

▼ -0.17 (-0.73%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 62%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$1.49B

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0Liquidez saludable · 14.58Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 13 ago 2026, 12:09 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$23.17

Change-0.73%

Shares Out64.36M

Market Cap$1.49B

Enterprise Value$995.14M

52W Range10.29 - 30.99

Beta-0.75

P/E-8.04

P/B3.18

P/FCF-11.03

EV/EBITDA-5.15

EV/FCF-7.36

Price$23.17

Change-0.73%

Shares Out64.36M

Market Cap$1.49B

Enterprise Value$995.14M

52W Range10.29 - 30.99

Beta-0.75

P/E-8.04

P/B3.18

P/FCF-11.03

EV/EBITDA-5.15

EV/FCF-7.36

Earnings Yield-12.43%

FCF Yield-9.07%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio14.58

Quick Ratio14.58

Target$32.57

Target Upside40.57%

Target Median$35.00

Target Range20.00 - 42.00

Volume808.88K

Avg Volume651.83K

EPS Surprise-0.29

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

84/100

Por qué este puntaje▼

Nivel de deuda manejable · 0Liquidez saludable · 14.58Rentabilidad débil

Analyst view

Analyst sentiment and price target

BCAX

Analyst sentiment

Based on 9 analyst votes · 2026-09-05

83/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-13

Bajo

$20.00

Promedio

$32.17

Mediana

$36.00

Alto

$42.00

Resumen de la compañía

IPO: 9/13/2024

Industria: Biotechnology

P/B i: 3.18

Deuda / Patrimonio i: 0.00

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 14.58

Ratio rápido: 14.58

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Cohlhepp Ryan

Transacción: 08/10/2026

VENTA

Cambio

-18,750

Precio

$3.79

Presentación

08/12/2026

Tipo

VENTA

Cohlhepp Ryan

Transacción: 08/10/2026

VENTA

Cambio

-18,750

Precio

$27.98

Presentación

08/12/2026

Tipo

VENTA

Mazumdar Claire

Transacción: 08/10/2026

VENTA

Cambio

-10,000

Precio

$3.79

Presentación

08/12/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Cohlhepp Ryan	VENTA	-18,750	$3.79	08/10/2026	08/12/2026
Cohlhepp Ryan	VENTA	-18,750	$27.98	08/10/2026	08/12/2026
Mazumdar Claire	VENTA	-10,000	$3.79	08/10/2026	08/12/2026
Mazumdar Claire	VENTA	-10,000	$27.98	08/10/2026	08/12/2026
Hyep Ivan	VENTA	-12,500	$3.79	08/10/2026	08/12/2026
Hyep Ivan	VENTA	-12,500	$27.97	08/10/2026	08/12/2026
Oliger Christy J.	OTRO	0	Not reported	07/28/2026	07/29/2026
Bender Jeremy	OTRO	0	Not reported	07/28/2026	07/29/2026
Oliger Christy J.	COMPRA	+38,950	$26.88	07/28/2026	07/29/2026
Bender Jeremy	COMPRA	+38,950	$26.88	07/28/2026	07/29/2026
Mazumdar Claire	VENTA	-10,000	$3.79	07/10/2026	07/14/2026
Mazumdar Claire	VENTA	-28	$29.68	07/10/2026	07/14/2026
Cohlhepp Ryan	VENTA	-536	$29.00	07/09/2026	07/10/2026
Hyep Ivan	VENTA	-908	$3.79	07/08/2026	07/10/2026
Hyep Ivan	VENTA	-830	$30.31	07/08/2026	07/10/2026
Cohlhepp Ryan	VENTA	-18,750	$3.79	07/08/2026	07/10/2026
Cohlhepp Ryan	VENTA	-1,075	$30.35	07/08/2026	07/10/2026
Simson Jake	COMPRA	+19,475	$20.56	06/09/2026	06/10/2026
POWELL MICHAEL	COMPRA	+19,475	$20.56	06/09/2026	06/10/2026
Robertson Scott M.	COMPRA	+19,475	$20.56	06/09/2026	06/10/2026

Sobre la compañía

Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Fuente - Link

Competidores

EYPT FTRE KURA MRVI PHAT PRME PROK SEPN SVRA TNGX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on September 1, 2026 to two new employees as a material inducement to employment under Bicara's 2026 Inducement Plan.

GlobeNewsWire

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August 12, 2026, it awarded an inducement grant to Jennifer Larson under Bicara's 2026 Inducement Plan as a material inducement to her commencement of employment as Bicara's Chief Financial Officer. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $24.63 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on August 12, 2026.

GlobeNewsWire

Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX

Dimensional Fund Advisors LP grew its holdings in Bicara Therapeutics Inc. (NASDAQ: BCAX) by 166.9% during the quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,261 shares of the company's stock after purchasing an additional 68,327 shares during the quarter. Dimensional

Defense World

Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds

Bicara Therapeutics (BCAX) is upgraded to 'Buy' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX's phase 1 data show promising median overall survival, but toxicity and small cohort size warrant caution ahead of pivotal phase 3 readout. Strong cash position ($500M liquidity) supports operations into 2029, enabling pursuit of interim phase 3 results and potential commercialization.

Seeking Alpha

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.

Benzinga

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-11	-0.64	-0.93	-0.29
2026-03-26	-0.72	-0.68	0.04
2025-11-10	-0.55	-0.67	-0.12
2025-08-12	-0.54	-0.5	0.04
2025-05-13	-0.4	-0.68	-0.28
2025-03-27	-0.31	-0.39	-0.08
2024-11-12	-0.46	-1.6	-1.14